DOCSLIB.ORG

The Role of RL13 in Human Cytomegalovirus Pathogenesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of RL13 in Human Cytomegalovirus Pathogenesis The Role of RL13 in Human Cytomegalovirus Pathogenesis A thesis submitted in candidature for the degree of DOCTOR OF PHILOSOPHY (PhD) by Carmen Grace Bedford December 2018 Division of Infection and Immunity, School of Medicine, Cardiff University Declaration This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ……………………………………………………… Date ………………….…………….……… STATEMENT 1 This thesis is being submitted in partial fulfilment of the requirements for the degree of PhD. Signed ………………………………………….…………… Date …………………………….…………… STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated, and the thesis has not been edited by a third party beyond what is permitted by Cardiff University’s Policy on the Use of Third-Party Editors by Research Degree Students. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ……………………………………….……….…… Date …………………….………………… STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available online in the University’s Open Access repository and for inter-library loan, and for the title and summary to be made available to outside organisations. Signed …………………………………………….…..….. Date ………………………………………… STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS I hereby give consent for my thesis, if accepted, to be available online in the University’s Open Access repository and for inter-library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed ……………………………………………..……… Date ………………………………….……… I II Acknowledgements I would first like to express my sincerest gratitude to my supervisors for the opportunity to undertake this PhD project. In particular to Dr Richard Stanton, whose support, guidance and patience with me throughout made this possible. Thank you for challenging me and allowing me to develop professionally and personally. I am always amazed at your capacity to multitask and your ability to appraise and return a piece of work so quickly! I am also very grateful to Prof Gavin Wilkinson for his guidance and valuable insight and to Dr Peter Tomasec who sadly is no longer with us but is fondly remembered. I would like to thank Health and Care Research Wales who have funded this thesis. I am very appreciative to Prof Robin Antrobus, Dr Mike Weekes and Dr Paul Lehner who performed the mass-spectrometry analysis of virions used in this work. I am indebted to all members of the HCMV and Adenovirus Research groups for their friendship, assistance and encouragement without which I would have struggled. Thank you, Dawn Roberts, for your help and answering my “stupid questions”, Dr Evelina Statkute for your guidance and Dr Isa Murrell for your constant enthusiasm in what RL13 does. Thank you, Dr Mihil Patel, for your company during Bake-Off season, Dr Simone Forbes for all the caffeine-fuelled laughs, and Dr Hester Nichols for your continued friendship and for maintaining my sanity with endless cups of tea and a great taste in films! Thank you to my parents, Mike and Linda, and the rest of the Bedford clan for their love, kindness, generosity and constant support. Tori, thank you for all the weekends and evenings away from the lab winning pots in the double – to this day no one knew who they were or what they were doing. Finally, to my fiancé Nathan, thank you for believing in me even when I didn’t believe in myself. Without you keeping me together I would never have made it here. I look forward to our next adventure together. “You miss 100% of the shots you don’t take. - Wayne Gretzky” - Michael Scott III IV Summary Human cytomegalovirus (HCMV) is the leading infectious cause of congenital malformation. In vitro propagation of HCMV strains that authentically represent clinical virus are required to facilitate effective research. However, this is problematic, since efficient replication of clinical HCMV strains in vitro is achieved only after mutations have been selected. The first gene to mutate is consistently RL13. RL13 encodes a virion envelope protein that suppresses release of infectious virus from cells. Despite mutation in cell culture it is conserved in clinical strains, indicating that it is important in vivo. However, it is unclear how RL13 inhibits virus in vitro, or what advantage it provides in vivo. RL13 expression did not affect genome replication or virion protein production, however it reduced the infectivity of released virions. Mass spectrometry revealed that RL13 expression altered the composition of released virions, however there was no obvious reason for these changes to effect infectivity. During virus spread, RL13 promoted cell- cell transfer of virus, reducing the ability of neutralising antibodies to inhibit virus spread in fibroblasts, however this effect was masked by UL128L expression in other cell types. Genetic analysis of RL13 from clinical strains revealed that RL13 sequences clustered into 9 distinct clades, with sequences from different clades retaining the ability to inhibit the release of infectious virus. A RL13 homologue from Rhesus CMV also restricted the release of infectious virus. This conservation of function suggests that the phenotype is not an artefact of in vitro culture conditions. RL13 on the cell surface bound human IgG, however it did not inhibit antibody-dependent cellular cytotoxicity during infection. This thesis has delivered insights into the role of RL13 during infection, has demonstrated the importance of using more clinically relevant RL13+ HCMV strains and will aid future research using such HCMV strains. V VI Table of Contents Declaration ...................................................................................................................................... I Acknowledgements ....................................................................................................................... III Summary ......................................................................................................................................... V Table of Contents ......................................................................................................................... VII List of Figures ................................................................................................................................ XII List of Tables ................................................................................................................................ XIV CHAPTER 1. INTRODUCTION ........................................................................................................ 1 1.1 Human Cytomegalovirus (HCMV) ......................................................................................... 2 1.1.1 The Herpesvirus Family ................................................................................................ 2 1.1.2 Discovery and Isolation ................................................................................................ 4 1.2 Clinical Importance and manifestations of HCMV infection ................................................ 5 1.2.1 Epidemiology ................................................................................................................ 5 1.2.2 Transmission and Primary Infection ............................................................................. 5 1.2.3 Infection in the Immunocompetent Host ..................................................................... 6 1.2.4 Congenital and Perinatal Infection ............................................................................... 6 1.2.5 Infection in at-risk groups ............................................................................................. 7 1.2.6 Treatments and Vaccination ........................................................................................ 8 1.3 Viral Particles ...................................................................................................................... 10 1.3.1 Components of Infectious virions ............................................................................... 10 1.3.2 Non-infectious Viral Particles ..................................................................................... 12 1.4 Viral Lifecycle ...................................................................................................................... 16 1.4.1 Virus Entry .................................................................................................................. 16 1.4.2 Viral DNA Replication and Gene Expression Regulation during Infection .................. 16 1.4.3 Viral Particle Maturation and Egress .......................................................................... 20 1.4.4 Latency and Reactivation ........................................................................................... 23 1.5 HCMV Infection .................................................................................................................. 24 VII 1.5.1 Intra-host Dissemination and Tropism ...................................................................... 24 1.5.2 Lessons from HCMV Infection in vitro ....................................................................... 25 1.5.3 The Immune Response and Immunomodulation ...................................................... 26 1.6 The Genetics of HCMV ......................................................................................................
Load more

Recommended publications
  • Repurposing the Human Immunodeficiency Virus (Hiv) Integrase
    REPURPOSING THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE INHIBITOR RALTEGRAVIR FOR THE TREATMENT OF FELID ALPHAHERPESVIRUS 1 (FHV-1) OCULAR INFECTION A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Matthew Robert Pennington August 2018 © 2018 Matthew Robert Pennington REPURPOSING THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE INHIBITOR RALTEGRAVIR FOR THE TREATMENT OF FELID ALPHAHERPESVIRUS 1 (FHV-1) OCULAR INFECTION Matthew Robert Pennington, Ph.D. Cornell University 2018 Herpesviruses infect many species, inducing a wide range of diseases. Herpesvirus- induced ocular disease, which may lead to blindness, commonly occurs in humans, dogs, and cats, and is caused by human alphaherpesvirus 1 (HHV-1), canid alphaherpesvirus (CHV-1), and felid alphaherpesvirus 1 (FHV-1), respectively. Rapid and effective antiviral therapy is of the utmost importance to control infection in order to preserve the vision of infected people or animals. However, current treatment options are suboptimal, in large part due to the difficulty and cost of de novo drug development and the lack of effective models to bridge work in in vitro cell cultures and in vivo. Repurposing currently approved drugs for viral infections is one strategy to more rapidly identify new therapeutics. Furthermore, studying ocular herpesviruses in cats is of particular importance, as this condition is a frequent disease manifestation in these animals and FHV-1 infection of the cat is increasingly being recognized as a valuable natural- host model of herpesvirus-induced ocular infection First, the current models to study ocular herpesvirus infections were reviewed.
    [Show full text]
  • Commission Directive (Eu)
    L 279/54 EN Offi cial Jour nal of the European Union 31.10.2019 COMMISSION DIRECTIVE (EU) 2019/1833 of 24 October 2019 amending Annexes I, III, V and VI to Directive 2000/54/EC of the European Parliament and of the Council as regards purely technical adjustments THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (1), and in particular Article 19 thereof, Whereas: (1) Principle 10 of the European Pillar of Social Rights (2), proclaimed at Gothenburg on 17 November 2017, provides that every worker has the right to a healthy, safe and well-adapted working environment. The workers’ right to a high level of protection of their health and safety at work and to a working environment that is adapted to their professional needs and that enables them to prolong their participation in the labour market includes protection from exposure to biological agents at work. (2) The implementation of the directives related to the health and safety of workers at work, including Directive 2000/54/EC, was the subject of an ex-post evaluation, referred to as a REFIT evaluation. The evaluation looked at the directives’ relevance, at research and at new scientific knowledge in the various fields concerned. The REFIT evaluation, referred to in the Commission Staff Working Document (3), concludes, among other things, that the classified list of biological agents in Annex III to Directive 2000/54/EC needs to be amended in light of scientific and technical progress and that consistency with other relevant directives should be enhanced.
    [Show full text]
  • B Directive 2000/54/Ec of the European
    02000L0054 — EN — 24.06.2020 — 002.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B DIRECTIVE 2000/54/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC) (OJ L 262, 17.10.2000, p. 21) Amended by: Official Journal No page date ►M1 Commission Directive (EU) 2019/1833 of 24 October 2019 L 279 54 31.10.2019 ►M2 Commission Directive (EU) 2020/739 of 3 June 2020 L 175 11 4.6.2020 02000L0054 — EN — 24.06.2020 — 002.001 — 2 ▼B DIRECTIVE 2000/54/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC) CHAPTER I GENERAL PROVISIONS Article 1 Objective 1. This Directive has as its aim the protection of workers against risks to their health and safety, including the prevention of such risks, arising or likely to arise from exposure to biological agents at work.
    [Show full text]
  • Characterization of Higher Order Chromatin Structures and Chromatin States in Cell Models of Human Herpesvirus Infection
    University of Vermont UVM ScholarWorks Graduate College Dissertations and Theses Dissertations and Theses 2021 Characterization Of Higher Order Chromatin Structures And Chromatin States In Cell Models Of Human Herpesvirus Infection Michael Mariani University of Vermont Follow this and additional works at: https://scholarworks.uvm.edu/graddis Part of the Biology Commons, Genetics and Genomics Commons, and the Virology Commons Recommended Citation Mariani, Michael, "Characterization Of Higher Order Chromatin Structures And Chromatin States In Cell Models Of Human Herpesvirus Infection" (2021). Graduate College Dissertations and Theses. 1424. https://scholarworks.uvm.edu/graddis/1424 This Dissertation is brought to you for free and open access by the Dissertations and Theses at UVM ScholarWorks. It has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized administrator of UVM ScholarWorks. For more information, please contact [email protected]. CHARACTERIZATION OF HIGHER ORDER CHROMATIN STRUCTURES AND CHROMATIN STATES IN CELL MODELS OF HUMAN HERPESVIRUS INFECTION A Dissertation Presented by Michael Mariani to The Faculty of the Graduate College of The University of Vermont In Partial Fulfilment of the Requirements For the Degree of Doctor of Philosophy Specializing in Cellular, Molecular, and Biomedical Sciences May, 2021 Defense Date: March 24, 2021 Dissertation Examination Committee: Seth Frietze, Ph.D., Advisor Matthew Poynter, Ph.D., Chairperson David Pederson Ph.D. Stephen Keller Ph.D. Cynthia J. Forehand, Ph.D., Dean of the Graduate College COPYRIGHT © Copyright by Michael Mariani May 2021 ABSTRACT Human herpesviruses are ubiquitous pathogens worldwide with 90% of the global population infected with one or more Human herpesviruses (HHV’s) by adulthood.
    [Show full text]
  • 2021.03.30.437686.Full.Pdf
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.30.437686; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Combined Nanopore and Single-Molecule Real-Time Sequencing Survey of Human Betaherpesvirus 5 Transcriptome Balázs Kakuk1#, Dóra Tombácz1,2,3#, Zsolt Balázs1, Norbert Moldován1, Zsolt Csabai1, Gábor Torma1, Klára Megyeri4, Michael Snyder3, Zsolt Boldogkői1* 1Department of Medical Biology, Faculty of Medicine, University of Szeged, Somogyi B. u. 4., 6720 Szeged, Hungary 2MTA-SZTE Momentum GeMiNI Research Group, University of Szeged, Somogyi B. u. 4., 6720 Szeged, Hungary 3Department of Genetics, School of Medicine, Stanford University, 300 Pasteur Dr, Stanford, California, USA 4Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, 6720, Hungary # The first two authors contributed equally to this work *To whom correspondence should be addressed: [email protected] ABSTRACT Long-read sequencing (LRS), a powerful novel approach, is able to read full-length transcripts and confers a major advantage over the earlier gold standard short-read sequencing in the efficiency of identifying for example polycistronic transcripts and transcript isoforms, including transcript length- and splice variants. In this work, we profile the human cytomegalovirus transcriptome using two third- generation LRS platforms: the Sequel from Pacific BioSciences, and MinION from Oxford Nanopore Technologies. We carried out both cDNA and direct RNA sequencing, and applied the LoRTIA software, developed in our laboratory, for the transcript annotations.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0042898A1 Berenson Et Al
    US 20170042898A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0042898A1 Berenson et al. (43) Pub. Date: Feb. 16, 2017 (54) METHODS AND COMPOSITIONS FOR Publication Classification TREATINGVIRAL OR VIRALLY-INDUCED (51) Int. Cl. CONDITIONS A63L/506 (2006.01) A6IR 9/00 (2006.01) (71) Applicants: HEMAQUEST A638/12 (2006.01) PHARMACEUTICALS, INC., San A6II 3/19 (2006.01) Diego, CA (US); TRUSTEES OF A6II 3/18 (2006.01) BOSTON UNIVERSITY, Boston, MA A6II 3/167 (2006.01) (US) A63L/4045 (2006.01) (72) Inventors: Ronald J. Berenson, Mercer Island, A6II 3/165. (2006.01) WA (US); Douglas V. Faller, Weston, A638/15 (2006.01) A6II 3/4402 (2006.01) MA (US) A6II 3/522 (2006.01) (73) Assignees: HEMAQUEST A6II 3/473 (2006.01) PHARMACEUTICALS, INC., San (52) U.S. Cl. Diego, CA (US); TRUSTEES OF CPC ........... A61 K3I/506 (2013.01); A61 K3I/522 BOSTON UNIVERSITY, Boston, MA (2013.01); A61K 9/0053 (2013.01); A61 K (US) 38/12 (2013.01); A61K 31/19 (2013.01); A61 K 3 1/473 (2013.01); A61K 31/167 (2013.01); (21) Appl. No.: 15/335,776 A61K 31/4045 (2013.01); A61K 3 1/165 (2013.01); A61K 38/15 (2013.01); A61 K (22) Filed: Oct. 27, 2016 3I/4402 (2013.01); A61K 31/18 (2013.01) Related U.S. Application Data (63) Continuation of application No. 14/728,592, filed on (57) ABSTRACT Jun. 2, 2015, now abandoned, which is a continuation of application No. 13/912,637, filed on Jun. 7, 2013, Provided are methods and compositions for the prevention now abandoned, which is a continuation of applica and/or treatment of viral conditions, virally-induced condi tion No.
    [Show full text]
  • Assessment of Viral RNA in Idiopathic Pulmonary Fibrosis Using RNA-Seq
    Assessment of Viral RNA in Idiopathic Pulmonary Fibrosis Using RNA-seq Qinyan Yin Tulane University School of Medicine Michael J Strong Tulane University School of Medicine Yan Zhuang Tulane University School of Medicine Erik K Flemington Tulane University School of Medicine Naftali Kaminski Yale University School of Medicine Joao de Andrade Vanderbilt University School of Medicine Joseph A Lasky ( [email protected] ) Research article Keywords: Idiopathic pulmonary brosis, IPF, RNA-seq, viruses, EBV, HCV, HERV-K, herpesvirus saimiri Posted Date: February 10th, 2020 DOI: https://doi.org/10.21203/rs.2.11953/v3 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on April 3rd, 2020. See the published version at https://doi.org/10.1186/s12890-020-1114-1. Page 1/20 Abstract Background Numerous publications suggest an association between herpes virus infection and idiopathic pulmonary brosis (IPF). These reports have employed immunohistochemistry, in situ hybridization and/or PCR, which are susceptible to specicity artifacts. Methods We investigated the possible association between IPF and viral RNA expression using next-generation sequencing, which has the potential to provide a high degree of both sensitivity and specicity. We quantied viral RNA expression for 740 viruses in 28 IPF patient lung biopsy samples and 20 age-matched controls. Key RNA-seq results were conrmed using Real-time RT- PCR for select viruses (EBV, HCV, herpesvirus saimiri and HERV-K). Results We identied sporadic low-level evidence of viral infections in our lung tissue specimens, but did not nd a statistical difference for expression of any virus, including EBV, herpesvirus saimiri and HERV-K, between IPF and control lungs.
    [Show full text]
  • Brief Communication
    BRIEF COMMUNICATION http://doi.org/10.1590/S1678-9946202062054 Frequency of congenital cytomegalovirus infections in newborns in the Sao Paulo State, 2010-2018 Carla Grasso Figueiredo1, Adriana Luchs1, Edison Luiz Durigon2, Danielle Bruna Leal de Oliveira2, Vanessa Barbosa da Silva2, Ralyria Melyria Mello2, Ana Maria Sardinha Afonso1, Maria Isabel de Oliveira 1 ABSTRACT Human cytomegalovirus (HCMV) infections remain a neglected public health issue. The aim of the present study was to evaluate the frequency of HCMV congenital infections in newborns up to 1 month in the Sao Paulo State, from 2010 to 2018. The molecular characterization of HCMV-positive samples was also undertaken. Urine samples from 275 potential congenital HCMV-infected patients were tested by real-time Polymerase Chain Reaction (qPCR). HCMV-positive samples were amplified by conventional PCR targeting the UL89 gene, sequenced and searched for mutations. A total of 32 (11.6%) positive- HCMV cases were detected (mean Ct 30.59); mean and median age of 10.3 and 6 days old, respectively. Children aged between 0-3 weeks had higher HCMV detection rates (84.4%; 27/32). UL89 gene was successfully sequenced in two samples, both classified as the human betaherpesvirus 5. No described resistance-associated mutations were identified. A routine screening in newborns coupled with the genetic characterization of key viral genes is vital to decrease sequels associated with congenital HCMV infections. KEYWORDS: Congenital cytomegalovirus infection. Real-time PCR. Surveillance. DNA sequencing. INTRODUCTION 1Instituto Adolfo Lutz, Centro de Virologia, Human Cytomegalovirus (HCMV) is a ubiquitous human-specific DNA virus, São Paulo, São Paulo, Brazil belonging to the Herpesviridae family1.
    [Show full text]
  • Supplementary Table S1
    Supplementary Information Intrinsically disordered regions are abundant in simplexvirus proteomes and display signatures of positive selection Alessandra Mozzi1*, Diego Forni1, Rachele Cagliani1, Mario Clerici2,3, Uberto Pozzoli1, Manuela Sironi1 1 Scientific Institute, IRCCS E. MEDEA, Bioinformatics, 23842 Bosisio Parini, Italy. 2 Department of Physiopathology and Transplantation, University of Milan, 20090 Milan, Italy. 3 Don C. Gnocchi Foundation ONLUS, IRCCS, 20148 Milan, Italy. * To whom correspondence should be addressed. Tel: +39-031877826; Fax: +39-031877499; Email: [email protected] Supplementary Tables: Supplementary Table S1. List of HSV-2 strains used for gammaMap analysis. Supplementary Table S2. List of herpesvirus strains used for intrinsic disorder analysis. Supplementary Table S3. Positively selected sites detected by gammaMap analysis. Supplementary Figures: Supplementary Figure S1. Comparison between γ and dN-dS values. Supplementary Figure S2. Fraction of disordered residues in VZV and HSV1. Supplementary Figure S3. Fraction of disordered residues among human proteins. Supplementary Table S1. List of HSV-2 strains used for gammaMap analysis. Strain Name GenBank ID Length Date Country Continent 2009-2222 MF510299 152219 - Botswana Africa Isolate 17 LT797636 138913 2006/2013 Burundi Africa 2006-17607 MF510281 152517 2006 Cameroon Africa Isolate 13 LT797623 138873 2006/2013 DRC Africa isolate 10 LT797629 138972 2006/2013 DRC Africa isolate 1 LT797627 138912 2006/2013 Guinea Africa Isolate 16 LT797624
    [Show full text]
  • Viral Infections in Burn Patients: a State-Of-The-Art Review
    viruses Review Viral Infections in Burn Patients: A State-Of-The-Art Review Jacek Baj 1,* , Izabela Korona-Głowniak 2 , Grzegorz Buszewicz 3 , Alicja Forma 3 , Monika Sitarz 4 and Grzegorz Teresi´nski 3 1 Chair and Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland 2 Department of Pharmaceutical Microbiology with the Laboratory of Microbiological Diagnostics, Medical University of Lublin, 20-090 Lublin, Poland; [email protected] 3 Chair and Department of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland; [email protected] (G.B.); [email protected] (A.F.); [email protected] (G.T.) 4 Department of Conservative Dentistry with Endodontics, Medical University of Lublin, 20-090 Lublin, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-662-094-014 Received: 1 October 2020; Accepted: 16 November 2020; Published: 17 November 2020 Abstract: Infections that are triggered by the accompanying immunosuppression in patients with burn wounds are very common regardless of age. Among burn patients, the most frequently diagnosed infections include the bacterial ones primarily caused by Pseudomonas aeruginosa or Klebsiella pneumonia, as well as fungal infections with the etiology of Candida spp. or Aspergillus spp. Besides, burn wounds are highly susceptible to viral infections mainly due to the impaired immune responses and defective functions of the immune cells within the wound microenvironment. The most prevalent viruses that invade burn wounds include herpes simplex virus (HSV), cytomegalovirus (CMV), human papilloma virus (HPV), and varicella zoster virus (VZV). Likewise, less prevalent infections such as those caused by the orf virus or Epstein–Barr Virus (EBV) might also occur in immunosuppressed burn patients.
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. The Interaction of Host and Viral MicroRNAs with Infectious Laryngotracheitis Virus Transcripts Jack Ferguson Thesis presented for the degree of Doctor of Philosophy The University of Edinburgh 2019 Declaration I declare that this thesis is of my own composition, and that it contains no material previously submitted for the award of any other degree. The work described in this thesis has been executed by myself, all work of other authors is duly acknowledged. Jack Ferguson Division of Infection and Immunity The Roslin Institute Royal (Dick) School of Veterinary Studies University of Edinburgh Easter Bush Campus Edinburgh Midlothian EH25 9RG ii Acknowledgements Firstly, I would like to thank my supervisors Bob Dalziel and Finn Grey. They have provided help, support and guidance throughout the duration of my PhD and listened irrespective of how daft the question/comment or suggestion may have been.
    [Show full text]
  • PCMV) in Wild Boars from Northeastern Patagonia, Argentina
    +Model RAM-436; No. of Pages 8 ARTICLE IN PRESS Revista Argentina de Microbiología xxx (xxxx) xxx---xxx R E V I S T A A R G E N T I N A D E MICROBIOLOGÍA www.elsevier.es/ram ORIGINAL ARTICLE Molecular detection of Porcine cytomegalovirus (PCMV) in wild boars from Northeastern Patagonia, Argentina a,b a,b a a Federico Andrés De Maio , Marina Winter , Sergio Abate , Diego Birochio , b,c a,b a,∗ Néstor Gabriel Iglesias , Daniel Alejandro Barrio , Carolina Paula Bellusci a Universidad Nacional de Río Negro, Sede Atlántica, Centro de Investigaciones y Transferencia Río Negro (CONICET-UNRN), Argentina b Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina c Universidad Nacional de Quilmes, Argentina Received 26 December 2019; accepted 18 December 2020 KEYWORDS Abstract Porcine cytomegalovirus (PCMV) is a recognized pathogen of domestic swine that is Infectious diseases of widely distributed around the world. PCMV is the etiological agent of inclusion body rhinitis swine; and has also been associated with other diseases that cause substantial losses in swine produc- Porcine tion. Wild boar populations can act as reservoirs of numerous infectious agents that affect pig cytomegalovirus; livestock, including PCMV. The aim of this work was to assess the circulation of this virus in free- Wild boars; living wild boars that inhabit Northeastern Patagonia (Buenos Aires and Río Negro Provinces), Northeast Patagonia Argentina. Nested-PCR assays were conducted to evaluate the presence of PCMV in samples of tonsil tissue collected from 62 wild boar individuals. It was found that the overall rate of infec- tion was about 56%, with significant higher values (almost 90%) in the age group corresponding to piglets (animals less than 6 months old).
    [Show full text]